EUVIMEDEUVIMED entdecken
Crossref

Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2

Mariem Galuia, Mark A. Socinski

AME Clinical Trials Review · 2026-06 · 4 · 30-30

DOI: 10.21037/actr-25-125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Mariem Galuia und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Galuia, M., & Socinski, M. A. (2026). Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2. AME Clinical Trials Review, 4, 30-30. https://doi.org/10.21037/actr-25-125

Vancouver

Galuia M, Socinski MA. Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2. AME Clinical Trials Review. 2026;4:30-30. doi:10.21037/actr-25-125

BibTeX
@article{Galuia2026,
  author = {Galuia, Mariem and Socinski, Mark A.},
  title = {Ivonescimab, a PD-1/VEGF bispecific antibody, challenges pembrolizumab monotherapy in PD-L1-positive non-small cell lung cancer: insights from HARMONi-2},
  journal = {AME Clinical Trials Review},
  year = {2026},
  volume = {4},
  pages = {30--30},
  doi = {10.21037/actr-25-125}
}
Kostenlos starten →